These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21596185)

  • 1. [Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes].
    Carné X
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():34-7. PubMed ID: 21596185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
    Feist E; Burmester GR
    Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
    Curran MP
    BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corneal response to canakinumab in cryopyrin associated periodic fever syndrome.
    Tsatsos M; Hawkin PN; Hossain P
    Br J Ophthalmol; 2013 Aug; 97(8):1081-2. PubMed ID: 23740963
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
    Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
    Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
    Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
    Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CAPS treatment].
    Jiménez Treviño S; Ramos Polo E
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization and clinical development of ILARIS(®) (canakinumab) for the treatment of autoinflammatory diseases.
    Gram H
    Curr Opin Chem Biol; 2016 Jun; 32():1-9. PubMed ID: 26720283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
    Mueller SM; Itin P; Haeusermann P
    Dermatology; 2011; 223(2):113-8. PubMed ID: 21967869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome.
    Mitroulis I; Skendros P; Ritis K
    Eur J Intern Med; 2010 Jun; 21(3):157-63. PubMed ID: 20493414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
    Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
    Savic S; McDermott MF
    Nat Rev Rheumatol; 2009 Oct; 5(10):529-30. PubMed ID: 19798026
    [No Abstract]   [Full Text] [Related]  

  • 19. [Canakinumab: a promising treatment in rheumatology].
    Fabreguet I; So A
    Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anakinra for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.